CNCT19
Commercial- Indications
- B-cell acute lymphoblastic leukemia
Company intelligence / Profile preview
Heyuan Biotechnology
Shanghai, Chinaoryzogen.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Heyuan Biotech's CD19-targeted CAR-T cell therapy drug product...approved for marketing...for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia. This is China's first CAR-T therapy for this indication... Plant-derived products have entered clinical trials; details on efficacy/safety not specified in public sources.
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-T cell therapyRecombinant proteinSmall molecule polypeptide
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Liji Biotechnology
Beyond the preview
Go deeper on Heyuan Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heyuan Biotechnology.